Insider Selling: Twist Bioscience Co. (NASDAQ:TWST) Director Sells 2,940 Shares of Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 2,940 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the transaction, the director now directly owns 18,173 shares of the company’s stock, valued at approximately $965,531.49. This represents a 13.93 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total value of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40.

Twist Bioscience Stock Down 1.8 %

Shares of NASDAQ TWST opened at $45.37 on Thursday. The firm has a fifty day simple moving average of $48.64 and a two-hundred day simple moving average of $45.98. The firm has a market capitalization of $2.71 billion, a PE ratio of -13.42 and a beta of 1.87. The company has a current ratio of 4.96, a quick ratio of 4.54 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 12 month low of $27.41 and a 12 month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. Twist Bioscience’s revenue was up 24.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.75) earnings per share. Equities analysts expect that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Barclays dropped their target price on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a report on Tuesday, November 19th. TD Cowen reiterated a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird raised their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. Finally, Scotiabank upped their price target on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.80.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TWST. Van ECK Associates Corp grew its stake in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at $34,000. Signaturefd LLC increased its stake in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after acquiring an additional 306 shares in the last quarter. US Bancorp DE lifted its position in Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares during the period. Finally, Beaird Harris Wealth Management LLC bought a new stake in Twist Bioscience during the third quarter worth about $95,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.